Autoplaque vs Strain AI
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a detailed, quantitative assessment of coronary artery plaque burden and luminal stenosis from CT angiography images. This tool is ideal for clinicians focused on precise heart attack risk stratification and guiding interventions based on the characterization of atherosclerotic plaque.
View Autoplaque →Choose Strain AI if…
Choose Strain AI if you require an AI-powered solution for rapid, on-device assessment of global longitudinal strain (GLS) from cardiac ultrasound images. This tool is best suited for physicians needing to quickly evaluate overall heart function and screen for conditions such as heart failure or cardiotoxicity at the point of care.
View Strain AI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Strain AI |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | On-device AI, operates without internet connection. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Strain AIStrain AI (Tool B) offers real-time, on-device AI insights with a simple interface, requiring minimal training for users to capture images and assess heart function. Autoplaque (Tool A), while providing automated segmentation, is a workstation-based post-processing application that requires appropriate training for its functions and limitations. The on-device, intuitive nature of Strain AI makes it more usable at the point of care.
Clinical Value
AutoplaqueAutoplaque (Tool A) provides FDA-cleared quantitative analysis of coronary plaques and luminal stenoses from CT angiography, aiding in heart attack risk prediction and treatment guidance, with the ability to quantify plaque as effectively as trained doctors. This advanced plaque characterization and long-term risk prediction from CCTA offers a deep, prognostic insight into cardiovascular health. While Strain AI (Tool B) offers valuable real-time GLS measurements for heart function, Autoplaque's specific focus on complex structural disease and predictive capabilities presents a distinct and high-impact clinical value.
Pricing & Value
Strain AIStrain AI (Tool B), as part of the Exo Iris system, has publicly available pricing for its device and a mandatory annual subscription that includes AI tools and workflow integration. This provides a clear cost structure, even if specific AI module pricing requires contact. Autoplaque (Tool A) has not disclosed its pricing, and its commercialization status through a licensee makes its cost less transparent.
Enterprise Readiness
Strain AIStrain AI (Tool B) explicitly states HIPAA compliance and BAA availability, which are critical for enterprise adoption. Its on-device AI deployment, operating without an internet connection, enhances security and simplifies IT integration, with full DICOM/PACS/VNA support. Autoplaque (Tool A) does not specify HIPAA compliance or BAA availability, and its workstation-based deployment may require more direct IT management.
Innovation
Strain AIStrain AI (Tool B) demonstrates significant innovation by delivering real-time, on-device AI insights for complex cardiac measurements like Global Longitudinal Strain on a portable ultrasound device, making advanced diagnostics accessible at the point of care. Autoplaque (Tool A) offers advanced quantitative analysis of coronary plaque from CT angiography, which is innovative for risk prediction, but Strain AI's approach to immediate, accessible, and multi-faceted on-device AI for ultrasound is arguably more disruptive to traditional workflows.
Support & Docs
Strain AIExo (Tool B) provides clear and specific support channels, including email, phone, and a ticket submission system, along with readily available user manuals and release notes. Autoplaque (Tool A), being developed by a medical center and licensed, lacks specific, publicly detailed support and documentation for the product itself, beyond general institutional contact information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Strain AI |
|---|---|---|
| Name | Autoplaque | Strain AI |
| Company | Cedars-Sinai Medical Center: AIM | Exo |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Exo's FDA-cleared Strain AI is an AI-powered medical software that analyzes cardiac ultrasound images to measure Global Longitudinal Strain (GLS), aiding physicians in assessing heart function and detecting conditions like heart failure and cardiotoxicity in adult patients. |
| Primary Imaging Modality | CT Angiography images | Cardiac ultrasound images |
| Key Analysis Focus | Quantitative analysis of coronary plaques and luminal stenoses | Global Longitudinal Strain (GLS) measurement |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Strain AI.